Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma
Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma
复制标题
DOI：
10.1210/jc.2003-030235
复制
发表时间：
2003-09-01
影响因子：
5.8
通讯作者：
Pacak, K
中科院分区：
文献类型：
--
作者：
Ilias, I;Yu, J;Pacak, K
本研究的目的是评估 6-[F-18]-氟多巴胺 ([F-18]-DA) 正电子发射断层扫描 (PET) 与 [I-131]-间碘苄胍 (MIBG) 闪烁扫描对转移性嗜铬细胞瘤 (PHEO) 患者的诊断效用。我们研究了 10 名男性和 6 名女性（平均年龄 38.2 +/- 11.5 岁），他们转至我们的机构进行转移性 PHEO 治疗；两名患者在两年内接受了两次研究。成像方式包括计算机断层扫描 (CT)、磁共振成像 (MRI)、[I-131]-MIBG 闪烁扫描和 [F-18]-DA PET。 16 名患者中有 15 名 CT 和/或 MRI 呈阳性结果，与嗜铬细胞瘤的存在一致。所有患者的 [F-18]-DAPET 均呈阳性，但 7 名患者的 [I-131]-MIBG 扫描呈阴性。 [F-18]-DA PET 和 [I-131]-MIBG 闪烁显像显示了 38 个摄取灶，仅通过 [F-18]-DA PET 显示了 90 个摄取灶，仅通过 [I-131]MIBG 显示了 10 个灶；大多数病变在 CT/MRI 上也可见。在这个最初的转移性嗜铬细胞瘤患者系列中，[F-18]DA PET 在所有患者中定位了 PHEO，并显示出大量 [I-131]-MIBG 闪烁扫描无法成像的病灶。因此，[F-18]-DA PET 被发现是转移性 PHEO 患者的一种优越的成像方法，其中正确检测疾病扩展通常决定最合适的治疗计划和未来的随访。
The purpose of the study was to assess the diagnostic utility of 6-[F-18]-fluorodopamine ([F-18]-DA) positron emission tomography scanning ( PET) vs. [I-131]-metaiodobenzylguanidine ( MIBG) scintigraphy in patients with metastatic pheochromocytoma (PHEO). We studied 10 men and six women ( mean age 38.2 +/- 11.5 yr) referred to our institution for metastatic PHEO; two patients were studied twice within a 2-yr interval. Imaging modalities included computed tomography (CT), magnetic resonance imaging (MRI), [I-131]-MIBG scintigraphy, and [F-18]-DA PET. Fifteen of 16 patients had positive findings on CT and/or MRI consistent with the presence of pheochromocytoma. [F-18]-DAPETwas positive in all patients, but seven patients had negative [I-131]- MIBG scans. Thirty-eight foci of uptake were shown by both [F-18]- DA PET and [I-131]- MIBG scintigraphy, 90 only by [F-18]- DA PET, and 10 only by [I-131]MIBG; most lesions were also visible on CT/ MRI. In this initial series of patients with metastatic pheochromocytoma, [F-18]DA PET localized PHEO in all patients and showed a large number of foci that were not imaged with [I-131]- MIBG scintigraphy. Thus, [F-18]- DA PET was found to be a superior imaging method in patients with metastatic PHEO, in which correct detection of disease extension often determines the most appropriate therapeutic plan and future follow-up.